$NVNO News

Last published 1w ago

1w agoNVNOenVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific SymposiumACCESS NewswireFeatured as an emerging technology and innovation in endovascular medicine, the presentation will highlight the potential of enVVe to address the significant unmet need in deep venous diseaseThe premier global forum for
1w agoNVNOenVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal StudyACCESS NewswireInitial 10-patient stage of U.S. pivotal study of the first-in-class enVVe non-surgical replacement venous valve on track to begin before year endCash and investments of $18.5 million expected to fund operations into Q4
3w agoNVNOenVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob BermanACCESS NewswireCEO-led series gives investors the story - straight talk, no B.S., no corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the next episode here IRVINE, CA /
1mo agoNVNOenVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal TrialACCESS NewswireLeading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe® System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal studyAn estimated 3 million
1mo agoNVNOenVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video SeriesACCESS NewswireNew CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spinReal answers to what investors need to know about enVVeno and why they need to know itWatch the inaugural
2mo agoNVNOenVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-DemandACCESS NewswireAccess the video webcast here Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation , today
2mo agoNVNOenVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand ConferenceACCESS NewswireVideo Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation today announced that Robert Berman, Chief
2mo agoAIM AKTX CNSP DARE+5JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsACCESS NewswireNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming
3mo agoNVNOIndependent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care TreatmentsACCESS NewswirePublished economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be
3mo agoNVNOenVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous ValveACCESS NewswireCompany Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the
3mo agoNVNOenVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" SegmentACCESS NewswireCEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease MarketWatch the "What This Means" video here IRVINE, CA / ACCESS
4mo agoNVNOenVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal TrialACCESS NewswireNew Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market
4mo agoNVNOenVVeno Medical to Present in the Webull Corporate Connect Webinar SeriesACCESS Newswire- Live webcast on Wednesday, June 24th at 2:00 PM ET- Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation ,a company
5mo agoNVNOenVVeno Medical to Participate in the Virtual Investor Closing Bell SeriesACCESS NewswireLive video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation
6mo agoNVNOenVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" SegmentACCESS NewswireFirst-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous ValveIDE approval positions enVVeno to advance what could become the first effective treatment option for the approximately 3
6mo agoNVNOenVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe SystemACCESS NewswireCompany ended the first quarter with approximately $25 million in cash and investmentsCapital on hand should fund operations through multiple key milestones into Q3 2027Company recently received FDA IDE approval to
6mo agoNVNOenVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous ValveACCESS NewswireFirst-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately 3 million U.S.
7mo agoNVNOenVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) SystemACCESS NewswireCompany accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiationStrong financial position expected to provide an operating runway into
9mo agoNVNOenVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price RequirementACCESS NewswireCompany achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closedReports Cash and Investments of approximately $28 million as of the Year Ended December 31, 2025IRVINE, CA /
11mo agoNVNOenVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect SegmentACCESS NewswireModerated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation
12mo agoNVNOenVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValveACCESS NewswireIRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation , a company setting new standards of care for the treatment of deep venous
1y agoNVNOenVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateACCESS Newswire- Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study- Cash burn of $4.2 million in Q3 remains in line with projected
1y agoNVNOenVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" SegmentACCESS NewswireWatch the "What This Means" video here
1y agoNVNOenVVeno Medical Updates Regulatory Status of VenoValve(R)ACCESS NewswireIRVINE, CA / ACCESS Newswire / September 15, 2025 / enVVeno Medical Corporation , a company setting new standards of care for the treatment of deep venous
1y agoNVNOenVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)ACCESS NewswireIRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation , a company setting new standards of care for the treatment of deep venous
1y agoAIM AKTX AMIX CNSP+5JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025ACCESS NewswireRegister for the three-day event here FRENCHTOWN, NJ / ACCESS Newswire / August 15, 2025 / JTC Team , a fully integrated corporate communications and investor relations firm, today announced its
1y agoNVNOenVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechACCESS Newswire- Live webcast on Thursday, August 21stat 2:00 PM ET IRVINE, CA / ACCESS Newswire / August 15, 2025 / enVVeno Medical Corporation , a company setting new
1y agoNVNOHealth Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous InsufficiencyACCESS NewswireClinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatmentsThe VenoValve could potentially save $5.9
1y agoNVNOenVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the CompanyACCESS Newswire- enVVeno is developing the VenoValve as a potential treatment option for the approximately 2.5 million patients in the U.S. suffering from severe deep Chronic Venous Insufficiency- FDA decision expected in 2H'2025-
1y agoNVNOenVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateACCESS Newswire- Cash burn of $3.8 million in Q2 remains in line with projected quarterly range- Cash and investments are sufficient to fund operations through Q3'2026 at current cash burn rate- Commercial readiness activities underway
1y agoNVNOenVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceACCESS Newswire- Video webcast now available on-demand IRVINE, CA / ACCESS Newswire / July 22, 2025 / enVVeno Medical Corporation , a company setting new standards of care
1y agoAIM AKTX AMIX CNSP+7JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand ConferenceACCESS Newswire- Video webcasts to be available on-demand Tuesday, July 22nd FRENCHTOWN, NJ / ACCESS Newswire / July 18, 2025 / JTC Team , a fully integrated corporate communications and investor relations firm, today
1y agoNVNOPositive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual MeetingACCESS NewswireInterim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline83% of subjects maintained a clinically
1y agoNVNOenVVeno Medical Appoints Jennifer Bright as Chief Financial OfficerACCESS NewswireIRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation , a company setting new standards of care for the treatment of deep venous disease,
1y agoNVNOThree-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular SurgeryACCESS NewswirePromising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and
1y agoNVNOenVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24ACCESS NewswireCash Burn of $4.0 million in Q1 remains in line with projected quarterly rangeCash and investments on hand are sufficient to fund operations beyond the anticipated FDA decision of VenoValve and the initiation of the
1y agoNVNOVenoValve to be Featured During Presentation at the 47th Annual Charing Cross SymposiumACCESS NewswireIRVINE, CA / ACCESS Newswire / April 23, 2025 / enVVeno Medical Corporation , a company setting new standards of care for the treatment of deep venous
1y agoNVNOenVVeno Medical to Participate in a Live Virtual Investor Closing Bell SegmentACCESS NewswireModerated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22nd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation
1y agoNVNOThe Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual SymposiumACCESS NewswireIRVINE, CA / ACCESS Newswire / March 31, 2025 / enVVeno Medical Corporation , a company setting new standards of care for the treatment of venous disease,
1y agoNVNOenVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25ACCESS NewswireCash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly rangeCash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the
1y agoNVNOenVVeno Medical Participates in the Virtual Investor "Top 5 for '25" On-Demand ConferenceACCESS NewswireOn-demand video webcast now available here IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation , a company setting new standards of
1y agoAKTX AMIX AREC CNSP+5Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-DemandACCESS Newswire- Access video webcasts from the first wave of participating companies hereFRENCHTOWN, NJ / ACCESS Newswire / February 19, 2025 / JTC Team , a fully integrated corporate communications and investor
1y agoNVNOOne-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous ForumACCESS NewswireOne-year follow-up data demonstrates sustained improvements across venous specific quality-of-life indicators.PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the
1y agoNVNOInterim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter MeetingACCESS NewswireTwo-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.78% of subjects maintained a clinically meaningful
1y agoNVNOenVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVeACCESS NewswireSuccessful Completion of All Planned Implants in GLP StudyenVVe Delivery System Demonstrates Consistent PerformanceCompany Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE,
1y agoNVNOenVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap WebsiteACCESS NewswireInterviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess the Recap
1y agoNVNOenVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH SymposiumACCESS Newswire85% Clinical Meaningful Benefit Responder Rate7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort75% Median Reduction in Pain 87% Median Ulcer Area Reduction97% Target Vein
1y agoNVNOenVVeno Medical Submits the VenoValve PMA Application Seeking FDA ApprovalACCESS NewswireDefinitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH SymposiumCompany to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00
2y agoNVNOenVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this YearACCESS NewswireContinued progress toward submission of 5th and final module of FDA premarket approval application for VenoValve® in Q4GLP study for enVVe® transcatheter-based replacement venous valve underway; On track
2y agoNVNOenVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)ACCESS NewswireFirst wave of implants successfully completed with updated delivery system performing very wellCompany on schedule to be in position to apply for approval for enVVe pivotal trial mid-2025 IRVINE, CA / ACCESSWIRE /